Answers are grounded in this paper and cite their sources.
Lu-177-PSMA-617 is a highly stable compound both in vitro and in vivo. Lu-177-PSMA-617 therapy seems to be a safe method for the treatment of castration-resistant prostate cancer patients. The fractionation regime that enables the longest duration of tumor control and/or survival will have to be developed in further studies.
No takes yet. Share an insight, caveat, or question.
Kabasakal et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: